$RVLP News
Last published 3y ago
- 3y agoRVLPRVL Pharmaceuticals plc Announces Prepackaged Reorganization of Certain U.S. SubsidiariesGlobeNewswireLender to Provide Incremental Liquidity to Support Long-Term Growth Senior Secured Lender to Exchange Outstanding Debt into Equity of the Reorganized Entities Business Operations at U.S. Subsidiaries to Continue as
- 3y agoRVLPRVL Pharmaceuticals plc to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewswireBRIDGEWATER, N.J., Aug. 23, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company, today announced that Brian Markison, Chief Executive Officer,
- 3y agoRVLPRVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq RulesGlobeNewswireBRIDGEWATER, N.J., Aug. 16, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline
- 3y agoRVLPRVL Pharmaceuticals plc (RVLP) Q2 2023 Earnings Call TranscriptEarnings Call Transcripts
- 3y agoRVLPRVL Pharmaceuticals plc Reports Second Quarter 2023 Financial Results; Provides Update on Strategic Business ReviewGlobeNewswire-- UPNEEQ® remains a significant potential value driver given its rapid early acceptance by providers, large total addressable market and untapped consumer opportunity -- -- Executed financing amendment with
- 3y agoRVLPRVL Pharmaceuticals plc to Discuss Second Quarter 2023 Financial Results and Provide Commercial UpdateGlobeNewswireBRIDGEWATER, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline
- 3y agoRVLPRVL Pharmaceuticals plc Provides Business UpdateGlobeNewswireBRIDGEWATER, N.J., July 05, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company organized in Ireland focused on the commercialization of
- 3y agoRVLPRVL Pharmaceuticals plc Announces Result of Proposal to Approve a Waiver of Offer Obligations under Rule 9 of the Irish Takeover Rules at Annual General MeetingGlobeNewswireBRIDGEWATER, N.J., June 15, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company, today announced results of the proposal to approve a waiver of
- 3y agoRVLPRVL Pharmaceuticals plc Reports First Quarter 2023 Financial Results; Provides Commercial UpdateGlobeNewswire-- First quarter 2023 UPNEEQ® net product sales grew 49%, or $2.9 million, over the prior year period to $8.8 million -- -- Enhanced operating leverage with a 32%, or $7.9 million, reduction in first quarter 2023
- 3y agoRVLPRVL Pharmaceuticals plc to Discuss First Quarter 2023 Financial Results and Provide Commercial UpdateGlobeNewswireBRIDGEWATER, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline
- 3y agoRVLPRVL Pharmaceuticals Announces that Upneeq® Wins "Best Eye Drop for Drooping Lids" NewBeauty in 13th Annual Beauty AwardsGlobeNewswireBRIDGEWATER, N.J., April 03, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company") announced today that its prescription eye drop Upneeq® (oxymetazoline hydrochloride ophthalmic
- 3y agoRVLPRVL Pharmaceuticals plc Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Commercial UpdateGlobeNewswire-- RVLP records exceptional year-over-year growth with UPNEEQ® launch into the medical aesthetics market -- -- Full year 2022 total revenues of $49.7 million, an increase of $32.2 million, or 184%, over 2021 -- --
- 3y agoRVLPRVL Pharmaceuticals plc to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Commercial UpdateGlobeNewswireBRIDGEWATER, N.J., March 15, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline
- 3y agoRVLPRVL Pharmaceuticals plc Announces Preliminary Fourth Quarter Sequential Growth of 21% and Full Year 2022 UPNEEQ® Net Product SalesGlobeNewswire-- Expects fourth quarter 2022 preliminary UPNEEQ net product sales of approximately $12.1 million, representing an increase of 21% over the third quarter 2022, and approximately $36.5 million for full year 2022 -- --
- 3y agoRVLPRVL Pharmaceuticals plc to Present at the Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic ConferenceGlobeNewswireBRIDGEWATER, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company, today announced that Brian Markison, Chief Executive Officer,
- 4y agoRVLPRVL Pharmaceuticals plc Reports Third Quarter 2022 Financial Results; Provides Commercial UpdateGlobeNewswire-- Third quarter 2022 UPNEEQ® net product sales of $10.0 million; 19% above second quarter 2022; 355% above third quarter 2021 -- -- Approximately 3,500 cumulative unique medical aesthetics practices placed
- 4y agoRVLPRVL Pharmaceuticals plc to Discuss Third Quarter 2022 Financial Results and Provide Commercial UpdateGlobeNewswireBRIDGEWATER, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline
- 4y agoRVLPRVL Pharmaceuticals plc Announces Preliminary Third Quarter 2022 UPNEEQ® Net Product SalesGlobeNewswire--Expects third quarter 2022 preliminary UPNEEQ net product sales of approximately $10.0 million, representing an increase of 19% over the second quarter 2022-- --Third quarter 2022 net product sales growth
- 4y agoRVLPRVL Pharmaceuticals plc to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewswireBRIDGEWATER, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, will present at the H.C. Wainwright 2
- 4y agoRVLPRevision Skincare® Announces Strategic Partnership with RVL Pharmaceuticals plcGlobeNewswireDALLAS and BRIDGEWATER, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Revision Skincare®, a leading medical-grade professional skincare brand, announced today a partnership with RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL"), the owner of UPNEEQ®, the first
- 4y agoRVLPRVL Pharmaceuticals plc Reports Second Quarter 2022 Financial Results; Provides Commercial UpdateGlobeNewswire-- Second quarter 2022 UPNEEQ® net product sales of $8.4 million; 42% above first quarter -- -- Opportunity for cash runway to extend through 2023 following recently announced financings -- -- Expanded Board of Directors with the appointment of Al
- 4y agoRVLPRVL Pharmaceuticals plc Announces Insider and Athyrium-Led FinancingGlobeNewswire-- Secured $68.9 million in committed financing through a combination of equity and non-dilutive debt financing -- -- Cash runway anticipated to extend through 2023 with $43.9 million funded at closing and an additional $25.0 million of availability t
- 4y agoRVLPRVL Pharmaceuticals plc to Discuss Second Quarter 2022 Financial Results and Provide Commercial UpdateGlobeNewswireBRIDGEWATER, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%
- 4y agoRVLPRVL Pharmaceuticals plc Announces Preliminary Second Quarter 2022 UPNEEQ® Net Product Sales ResultsPR Newswire-- Expects second quarter 2022 preliminary UPNEEQ net product sales of approximately $8.4 million, representing an increase of 42% from the first quarter 2022 -- -- Second quarter 2022 net product sales growth contributes to approximately $14.4 mil
- 4y agoRVLPRVL Pharmaceuticals plc Announces Preliminary Second Quarter 2022 UPNEEQ® Net Product Sales ResultsGlobeNewswire-- Expects second quarter 2022 preliminary UPNEEQ net product sales of approximately $8.4 million, representing an increase of 42% from the first quarter 2022 -- -- Second quarter 2022 net product sales growth contributes to approximately $14.4 mill
- 4y agoRVLPRVL Pharmaceuticals plc Announces Result of Proposal 3 at Annual General MeetingGlobeNewswireBRIDGEWATER, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company, today announced results of the Company's Annual General Meeting. At the Annual General Meeting
- 4y agoRVLPRVL Pharmaceuticals plc to Present at Upcoming ConferencesGlobeNewswireBRIDGEWATER, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, will present at two upcoming conferenc
- 4y agoRVLPRVL Pharmaceuticals plc Reports First Quarter 2022 Financial Results; Provides Commercial UpdateGlobeNewswireFirst quarter 2022 UPNEEQ net product sales of $5.9 million; 90% growth over fourth quarter 2021 First quarter 2022 total revenues of $21.4 million, inclusive of $15.5 million from Santen License Agreement, with related cash receipt in April 2022 R
- 4y agoRVLPUPNEEQ® Wins Best Professional-Treatment Product by Shape Magazine in the 2022 "Shape Healthy Skin Awards"PR NewswireBRIDGEWATER, N.J., May 9, 2022 /PRNewswire/ -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company") announced today that its FDA approved ptosis drug Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1% has received another indust
- 4y agoRVLPRVL Pharmaceuticals plc to Discuss First Quarter 2022 Financial Results and Provide Commercial UpdateGlobeNewswireBRIDGEWATER, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company, today announced that the Company will release its first quarter 2022 financial results and provide a
- 4y agoRVLPUPNEEQ® Wins "Best in Innovation" Award from New BeautyPR Newswire12th Annual Beauty Awards Selected from over 10,000 Entrants BRIDGEWATER, N.J. , April 6, 2022 /PRNewswire/ -- RVL Pharmaceuticals plc (NASDAQ:RVLP) announced today that its U.S. FDA approved acquired blepharoptosis (ptosis) drug UPNEEQ® (oxymetazo
- 4y agoRVLPRVL Pharmaceuticals plc Announces Preliminary First Quarter 2022 UPNEEQ® Net Product Sales ResultsGlobeNewswire-- Expects first quarter 2022 preliminary UPNEEQ net product sales of approximately $5.9 million, representing an increase of 90% from the fourth quarter 2021 -- -- Reaffirms fourth quarter 2022 guidance of $20 to 25 million in UPNEEQ net product sale
- 4y agoRVLPRVL Pharmaceuticals plc Reports Fourth Quarter and Full Year 2021 Financial Results; Provides Preliminary First Quarter 2022 UPNEEQ® Revenue Estimate and Business UpdateGlobeNewswireFourth quarter 2021 UPNEEQ product sales of $3.1 million, representing 39% growth over third quarter sales Fourth quarter and full year 2021 total revenues of $2.9 million and $17.5 million, respectively Full national launch of UPNEEQ into medical
- 4y agoRVLPRVL Pharmaceuticals to Present at the Barclays Global Healthcare Conference 2022GlobeNewswireBRIDGEWATER, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James "JD" Schaub, Chief Operating O
- 4y agoOSMTRVLPOsmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol "RVLP," Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales GuidanceGlobeNewswire-- Fourth Quarter 2021 net sales for UPNEEQ grew by approximately 41% to $3.1 million compared to the third quarter 2021 -- -- Fourth Quarter 2022 net sales for UPNEEQ targeted to range from $20-$25 million -- -- Full national launch into medical a